ロード中...
HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in basel...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020-06-01
|
| シリーズ: | Frontiers in Cellular and Infection Microbiology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/article/10.3389/fcimb.2020.00325/full |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|